Miracle drug: Guidelines issued for hepatitis C treatment
Guidelines for treatment with the new drug have been issued for healthcare professionals
Guidelines for treatment with the new drug have been issued for healthcare professionals. PHOTO: EXPRESS
ISLAMABAD:
Health ministry has issued guidelines for the treatment of hepatitis C in the wake of new drugs being introduced in to the market.
The Pakistan Health Research Council, a subsidiary organisation of the Ministry of National Health Services Regulations and Coordination, has issued guidelines for treatment of the disease after consultation with the provincial department and other stakeholders.
The Centers for Disease Control and Prevention (CDC), USA, has also helped the Pakistani government prepare these guidelines. Owing to the high prevalence rate of the disease in the country, the Drug Regulatory Authority of Pakistan recently registered 11 companies to sell the generic versions of Sofosbuvir, the new miracle therapy for the treatment of hepatitis C.
The price of the drug has been fixed at Rs5,868 (for 28 tablets) on a cost-plus-formula basis. Guidelines for treatment with the new drug have been issued for healthcare professionals.
Published in The Express Tribune, September 23rd, 2016.
Health ministry has issued guidelines for the treatment of hepatitis C in the wake of new drugs being introduced in to the market.
The Pakistan Health Research Council, a subsidiary organisation of the Ministry of National Health Services Regulations and Coordination, has issued guidelines for treatment of the disease after consultation with the provincial department and other stakeholders.
The Centers for Disease Control and Prevention (CDC), USA, has also helped the Pakistani government prepare these guidelines. Owing to the high prevalence rate of the disease in the country, the Drug Regulatory Authority of Pakistan recently registered 11 companies to sell the generic versions of Sofosbuvir, the new miracle therapy for the treatment of hepatitis C.
The price of the drug has been fixed at Rs5,868 (for 28 tablets) on a cost-plus-formula basis. Guidelines for treatment with the new drug have been issued for healthcare professionals.
Published in The Express Tribune, September 23rd, 2016.